Anti-asthmatic properties of a new peroral drug (HC 20-5II).
A clinical trial was performed with a new substance (HC 20-511) derived from the cycloheptothiophene group used in the management of asthma. Twenty-four asthma patients were treated at random, with HC 20-511 or placebo or the antihistaminic substance, clemastin (Tavegyl). A statistical evaluation of the results unequivocally demonstrates good protection with a single dose of 2.0 mg or two times 1.0 mg for 3 days against a challenging antigen, compared with the placebo or the antihistaminic agent. Tolerance was excellent.
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D002974:Clemastine / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003508:Cycloheptanes / Q000009:adverse effects; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D014797:Vital Capacity
D003508:Cycloheptanes; D010880:Piperidines; D010919:Placebos; D013876:Thiophenes; D002974:Clemastine